Recently, LM-350 (a CDH17 Antibody-Drug Conjugate), an innovative drug independently developed by LaNova Medicines, a wholly-owned subsidiary of Sino Biopharm (1177.HK), has received an Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA). 

LM-350 is an Antibody-Drug Conjugate (ADC) targeting CDH17, developed based on LaNova Medicines' next-generation ADC platform, LM-ADCTM. It can bind to CDH17 with high selectivity and has strong internalization capabilities. LM-350 uses a wild-type IgG1 configuration and also possesses antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Preclinical studies have shown that LM-350 exhibits significant anti-neoplasm activity in multiple xenograft models, with particularly outstanding effects in colorectal cancer xenograft models resistant to MMAE or irinotecan. 

CDH17 plays an important role in the invasion and metastasis of various neoplasms and is highly expressed in approximately 99% of colon cancers, 86% of adenocarcinoma gastric, 79% of oesophageal adenocarcinomas, and 50% of ductal adenocarcinomas of the pancreas^[1,2]. Gastrointestinal neoplasms (including colorectal cancer, gastric cancer, pancreatic carcinoma, esophageal cancer, etc.) are among the cancer types with the highest incidence and mortality rates globally. In 2022, the number of new patients worldwide exceeded 4 million, representing a huge unmet clinical need^[3]. 

Previously, LM-350 had received IND approval from the U.S. Food and Drug Administration (FDA) and completed the enrollment of the first patient in Australia in September 2025. With this IND approval in China, LaNova Medicines will continue to accelerate clinical research in China, aiming to provide patients with new treatment options as soon as possible.